The global life science and chemical instruments market is set to witness remarkable expansion, reaching an estimated value of USD 47.5 billion in 2024. With a steady compound annual growth rate (CAGR ...

La empresa local de secuenciación genética citó ahorros de costos para alinearse con su futura estrategia comercial.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth ...

Over the past year, the shadow of the Grail deal has hung over Illumina despite its reinvigorated leadership and launch of new partnerships or products, namely the MiSeq i100 benchtop sequencer.

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

The Genomics Core offers a wide range of genomic and DNA/RNA services. We operate the Illumina NovaSeq X Plus, NextSeq 550, and MiSeq platforms for all Next Generation Sequencing and offer an ...

Trade war with China? Check. Cuts to scientific research? Check.

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers explore cellular behavior mapped across complex tissues. The announcement ...

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant. While Illumina is still assessing the ...